Stockscreener 앱 받기
12.45
0.80%
-0.10
시간 외 거래:
12.44
-0.010
-0.08%
전일 마감가:
$12.55
열려 있는:
$12.89
하루 거래량:
249.68K
Relative Volume:
0.48
시가총액:
$213.53M
수익:
$13.11M
순이익/손실:
$-124.02M
주가수익비율:
-0.873
EPS:
-14.261
순현금흐름:
$-107.25M
1주 성능:
-1.66%
1개월 성능:
+26.01%
6개월 성능:
-12.88%
1년 성능:
-67.22%
1일 변동 폭
$12.25
$12.90
1주일 범위
$12.25
$13.16
52주 변동 폭
$9.40
$37.56
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
12.45 | 212.50M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript - AOL.com
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Tonix (TNXP) Daily Snapshot: Finishes 0.16% Higher at $12.68 in Latest Trading; the $12.05 to $13.31 Range Remains in Focus under the Current SnapshotValue Area High - Vinanet
Why TNXP Stock Is Suddenly Back On Retail Radar - stocktwits.com
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline - MarketBeat
Tonix Pharmaceuticals (TNXP) 10K Form and Latest SEC Filings 2026 - MarketBeat
Tonix Pharmaceuticals (TNXP) Holds Ground at $12.66 as Traders Eye $13.29 ResistanceTrend Reversal Picks - vinanet.vn
Tonix Pharmaceuticals Holding Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNXP) 2026-08-14 - Seeking Alpha
Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants - Stock Titan
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan
TNXP Q2 2026 Earnings: Better-Than-Expected Loss per Share, Shares Dip 3%Guidance Accuracy Score - Vinanet
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Tonix Pharmaceuticals Holding Corp.Common Stock (NQ: TNXP - FinancialContent
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance UK
Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns - simplywall.st
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build By Investing.com - Investing.com UK
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build - Investing.com India
Tonix Pharmaceuticals: TONMYA Refills Surge 207% As Coverage Reaches 136 Million U.S. Lives - Pulse 2.0
Tonix Pharma earnings beat by $0.27, revenue topped estimates - Investing.com Nigeria
Tonix Delivers A Beat, But The Real Test Starts Now (NASDAQ:TNXP) - Seeking Alpha
Raymond James raises Tonix Pharma stock price target on strong sales - Investing.com UK
Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal? - Kalkine Media
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Cal - GuruFocus
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... - Yahoo Finance UK
Tonix Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
TNXP: Tonmya's launch fueled major Q2 revenue growth and pipeline progress, with cash runway into 2027 - TradingView
Earnings call transcript: Tonix beats Q2 2026 estimates as TONMYA sales surge - Investing.com Nigeria
Tonix Pharmaceuticals Holding Releases Q2 2026 Financial Results - AlphaStreet
TNXP: TONMYA sales nearly tripled in Q2 2026, driving revenue growth and supporting robust pipeline progress - TradingView
Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results - MarketBeat
TNXP: Q2 2026 net revenue reached $13.5M, driven by TONMYA's 197% QoQ sales growth - tradingview.com
Q2 2026 Tonix Pharmaceuticals Holding Corp Earnings Call Transcript - GuruFocus
Is Tonix Pharmaceuticals (TNXP) Overvalued After Q2 Earnings Rep - GuruFocus
TNXP Looks 584.3% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. 2Q 2026: Revenue $13.54M, EPS ($2.44) — 10-Q Summary - TradingView
Tonix Q2 FY26 net loss narrows to $40.55 million; product revenue rises to $13.54 million - Bitget
Tonix Pharmaceuticals posts $13.5M Q2 product revenue, $40.6M net loss - TradingView
Tonix Pharmaceuticals Reports Q2 Revenue of $13.5 Million - Quiver Quantitative
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights - The Manila Times
TNXP: Q2 2026 revenue soared 575% year-over-year, driven by TONMYA sales and expanded coverage - TradingView
Insider Buyers At Tonix Pharmaceuticals Holding Recover Some Losses, But Still Down US$57k - webull.com
TNXP Looks 587.4% Overvalued on GF Value™ - GuruFocus
TONIX PHARMACEUTICALS HLDG Q2 2026 Earnings Preview: Recent $TNXP Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a shareEarnings Preview - TradingView
The Technical Signals Behind (TNXP) That Institutions Follow - Stock Traders Daily
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):